Form 4: Eli Lilly Executive Acquires Shares, Transfers to Trust

Eli Lilly & Co. EVP Jacob Van Naarden reported the acquisition of 4,865.888 shares of common stock and a transfer of 5,302 shares to a spousal lifetime access trust.

Summary

• Jacob Van Naarden, EVP, President of LLY Oncology & Head of Corporate Business Development, acquired 4,865.888 shares of Eli Lilly & Co. common stock on February 9, 2026, at a price of $1,044.67 per share.
• Following this transaction, Van Naarden directly beneficially owns 26,626.498 shares.
• Additionally, on February 5, 2026, Van Naarden's spouse transferred 5,302 shares of Eli Lilly and Company common stock to a Spousal Lifetime Access Trust (SLAT), of which Van Naarden is the trustee and a beneficiary.
• This transfer included 1,000 spouse-held shares previously reported as directly held due to an administrative error.
• Van Naarden indirectly beneficially owns 4,342 shares through the Van Naarden Family Trust and 5,302 shares through the SLAT.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as an executive's acquisition of shares typically indicates confidence in the company, though the trust transfer is primarily for estate planning.

Positives

• An executive acquiring shares can signal confidence in the company's future prospects.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider purchases, even if part of a pre-arranged plan, can sometimes be interpreted by the market as a sign of management's confidence in the company's future performance, especially in the pharmaceutical sector where long-term drug development pipelines are critical.

Comparison to Industry Standards

• No specific industry benchmarks or comparable company data are provided in this Form 4 filing to allow for a direct comparison of these transactions to industry standards.

Related Party Transactions

• Transfer of 5,302 shares by the Reporting Person's spouse to a Spousal Lifetime Access Trust (SLAT), where the Reporting Person is the trustee and a beneficiary.

Stakeholder Impact

• Shareholders may view the executive's share acquisition as a positive indicator of management confidence.
• The trust transfer is primarily an estate planning matter for the executive and their family, with no direct operational impact on employees, customers, suppliers, or creditors.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The executive's share acquisition signals confidence, which is a positive, but it's a routine insider transaction and not substantial enough to warrant a change in investment thesis for a company of Eli Lilly's size and market position. The trust transfer is an estate planning event and does not impact the company's fundamentals.

Keywords

Eli Lilly, LLY, Jacob Van Naarden, Insider Trading, Form 4, Stock Acquisition, Beneficial Ownership, Spousal Lifetime Access Trust, SLAT, Executive Stock Purchase